miR-564 的表达降低与骨肉瘤患者的预后不良相关。

Reduced expression of miR-564 is associated with worse prognosis in patients with osteosarcoma.

机构信息

Department of Orthopedics, The Second Hospital of Jilin University, Changchun, Jilin, China.

出版信息

Eur Rev Med Pharmacol Sci. 2018 Sep;22(18):5851-5856. doi: 10.26355/eurrev_201809_15912.

DOI:10.26355/eurrev_201809_15912

PMID:30280765

Abstract

OBJECTIVE

MiR-564 has been reported to be involved in the development of several types of cancers. However, its clinical significance in osteosarcoma (OS) has not been investigated. We aimed to explore the prognostic value of miR-564 in OS patients.

PATIENTS AND METHODS

Quantitative RT-PCR assay was used to detect the expression levels of miR-564 in OS tissues and matched normal bone tissues. The correlation between miR-564 expression and clinicopathological features was analyzed by Pearson's χ2-test. The disease-free survival and overall survival rates of OS patients were calculated by the Kaplan-Meier method. Cox regression analysis was used to assess factors related to survival.

RESULTS

We observed that the level of miR-564 was significantly reduced in OS tissues compared with that in the paired noncancerous bone tissues (p < 0.01). In addition, low miR-564 expression was found to be closely correlated with advanced clinical stage (p = 0.000) and distant metastasis (p = 0.003). Furthermore, survival analyses showed that patients with low expression of miR-564 had a shorter overall survival (p = 0.001) and disease-free survival (p = 0.001) than those with high expression of miR-564. Finally, we showed that miR-564 was an independent poor prognostic factor for both 5-year overall survival (p = 0.001) and 5-year disease-free survival (p = 0.001) through multivariate analysis.

CONCLUSIONS

Overall, our data for the first time suggest that downregulated miR-564 may be used as a novel prognosis predictor of OS.

摘要

目的

已有研究报道 miR-564 参与了多种类型癌症的发生发展。然而，其在骨肉瘤（OS）中的临床意义尚未被研究。本研究旨在探讨 miR-564 在 OS 患者中的预后价值。

方法

采用定量 RT-PCR 法检测 OS 组织及配对正常骨组织中 miR-564 的表达水平。采用 Pearson χ2 检验分析 miR-564 表达与临床病理特征的相关性。采用 Kaplan-Meier 法计算 OS 患者的无病生存率和总生存率。采用 Cox 回归分析评估与生存相关的因素。

结果

我们发现 miR-564 在 OS 组织中的表达水平明显低于配对的非癌性骨组织（p<0.01）。此外，低 miR-564 表达与较晚的临床分期（p=0.000）和远处转移（p=0.003）密切相关。生存分析显示，miR-564 低表达患者的总生存率（p=0.001）和无病生存率（p=0.001）均明显低于 miR-564 高表达患者。最后，我们通过多因素分析发现，miR-564 是 OS 患者 5 年总生存率（p=0.001）和 5 年无病生存率（p=0.001）的独立预后不良因素。